Fig. 5: Gene expression of benign prostate cells compared to NEPC transcriptomes and epigenomes.
From: Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
a Gene set enrichment analysis of genes specifically expressed in neuroendocrine, basal, and luminal cells from normal prostate73. Genes are ranked by differential expression in NEPC and PRAD LuCaP PDXs. b Overlap of NEPC-enriched H3K27ac peaks (Ne-CREs; n = 14,985; top) and FOXA1-binding sites (Ne-FOXA1; n = 20,935; bottom) with a 200 kb windows centered on the transcriptional start sites of the 20 most significantly differentially expressed genes in each indicated prostate cell type73. Box boundaries correspond to 1st and 3rd quartiles; whiskers extend to a maximum of 1.5x the inter-quartile range. p-values correspond to two-sided Wilcoxon test of Ne-CRE/Ne-FOXA1 peak overlap near neuroendocrine cell genes versus all other indicated gene categories. c Fraction of CpG methylation detected by whole-genome bisulfite sequencing in normal prostates tissue and PRAD at Ne-CREs and Ad-CREs. Methylation levels at H3K27ac peaks identified in epithelial keratinocytes or in peripheral blood monocytes are included for comparison. x-axis corresponds to peak center ±3 kb.
